Article · Wikipedia archive · Last revised May 31, 2026

Chlorproguanil/dapsone

Chlorproguanil/dapsone was a fixed dose antimalarial combination containing chlorproguanil and dapsone, which act synergistically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.

Last revised
May 31, 2026
Read time
≈ 1 min
Length
102 w
Citations
2
Source
Wikipedia ↗
Chlorproguanil/dapsone
Combination of
ChlorproguanilAntimalarial drug
DapsoneAntibiotic
Legal status
Legal status
  • Withdrawn
Identifiers
CAS Number

Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone,1 which act synergistically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.2

References

References

  1. Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". The Lancet. Infectious Diseases. 3 (3): 162–8. doi:10.1016/S1473-3099(03)00547-4. PMID 12614733.
  2. Luzzatto L (August 2010). "The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics". Lancet. 376 (9742): 739–41. doi:10.1016/S0140-6736(10)60396-0. PMID 20599264. S2CID 34866078.